APA (7th ed.) Citation

Pinter, M., Sieghart, W., Reiberger, T., Rohr‐Udilova, N., Ferlitsch, A., & Peck‐Radosavljevic, M. (2012). The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma - a pilot study. Alimentary Pharmacology & Therapeutics, 35(1), 83. https://doi.org/10.1111/j.1365-2036.2011.04896.x

Chicago Style (17th ed.) Citation

Pinter, M., W. Sieghart, T. Reiberger, N. Rohr‐Udilova, A. Ferlitsch, and M. Peck‐Radosavljevic. "The Effects of Sorafenib on the Portal Hypertensive Syndrome in Patients with Liver Cirrhosis and Hepatocellular Carcinoma - a Pilot Study." Alimentary Pharmacology & Therapeutics 35, no. 1 (2012): 83. https://doi.org/10.1111/j.1365-2036.2011.04896.x.

MLA (9th ed.) Citation

Pinter, M., et al. "The Effects of Sorafenib on the Portal Hypertensive Syndrome in Patients with Liver Cirrhosis and Hepatocellular Carcinoma - a Pilot Study." Alimentary Pharmacology & Therapeutics, vol. 35, no. 1, 2012, p. 83, https://doi.org/10.1111/j.1365-2036.2011.04896.x.